Valuation: Sanofi

Market Cap 95.43B 109B 88.86B 81.73B 153B 10,388B 156B 1,054B 413B 5,152B 408B 399B 17,800B P/E 2026 *
11.9x
P/E 2027 * 11x
Enterprise Value 105B 120B 97.99B 90.13B 169B 11,455B 172B 1,163B 455B 5,681B 450B 440B 19,628B EV / Sales 2026 *
2.23x
EV / Sales 2027 * 2.02x
Free-Float
89%
Yield 2026 *
5.36%
Yield 2027 * 5.67%
1 week+1.04%
Current month+3.72%
1 month+4.28%
3 months-1.02%
6 months-2.01%
Current year-5.80%
1 week 37.2
Extreme 37.2
39.8
1 month 36.4
Extreme 36.4
39.8
Manager TitleAgeSince
Chief Executive Officer 65 2026-04-30
Director of Finance/CFO 64 2024-03-31
Chief Tech/Sci/R&D Officer 51 2023-09-10
Director TitleAgeSince
Director/Board Member 60 2019-04-29
Director/Board Member 57 2020-04-27
Director/Board Member 64 2020-04-27
Change 5-day change 1-year change 3-year change Capi.($)
+2.05%-2.06%-8.45% - 106B
+1.93%+3.85%+51.05%+166.24% 1,068B
+0.29%+6.43%+60.47%+52.87% 641B
+2.45%+2.77%+39.61%+74.48% 454B
+2.17%+10.22%+41.17%+36.56% 351B
+1.46%+3.87%+39.70%+44.49% 299B
+0.40%+3.59%+19.93%+17.02% 266B
+2.73%+3.50%-25.66%-36.53% 220B
+4.48%+7.33%+30.47%+66.31% 203B
+2.91%+3.10%+18.84%+74.76% 162B
Average +2.18%+4.51%+26.71%+55.13% 407.04B
Weighted average by Cap. +1.96%+4.79%+38.62%+80.10%

Financials

2026 *2027 *
Net sales 47.15B 53.73B 43.91B 40.39B 75.71B 5,133B 77.01B 521B 204B 2,546B 202B 197B 8,795B 50.34B 57.36B 46.87B 43.11B 80.82B 5,480B 82.2B 556B 218B 2,717B 215B 211B 9,389B
Net income 8.44B 9.61B 7.86B 7.23B 13.55B 918B 13.78B 93.2B 36.48B 455B 36.09B 35.31B 1,574B 9.44B 10.75B 8.79B 8.08B 15.15B 1,027B 15.41B 104B 40.81B 509B 40.37B 39.5B 1,760B
Net Debt 9.8B 11.17B 9.13B 8.4B 15.74B 1,067B 16.01B 108B 42.39B 529B 41.94B 41.03B 1,829B 6.15B 7B 5.72B 5.26B 9.87B 669B 10.04B 67.89B 26.57B 332B 26.29B 25.72B 1,146B
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
-
Date Price Change
26-07-28 €39.80 +2.05%
26-07-27 €39.00 +2.63%
26-07-24 €38.00 0.00%
26-07-23 €38.00 -1.55%
26-07-22 €38.60 +0.52%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
79.38EUR
Average target price
96.14EUR
Spread / Average Target
+21.11%

Quarterly revenue - Rate of surprise